Published online Dec 26, 2014. doi: 10.4330/wjc.v6.i12.1270
Revised: July 27, 2014
Accepted: October 31, 2014
Published online: December 26, 2014
Processing time: 191 Days and 10 Hours
Cardiac resynchronization therapy (CRT) effected via biventricular pacing has been established as prime therapy for heart failure patients of New York Heart Association functional class II, III and ambulatory IV, reduced left ventricular (LV) function, and a widened QRS complex. CRT has been shown to improve symptoms, LV function, hospitalization rates, and survival. In order to maximize the benefit from CRT and reduce the number of non-responders, consideration should be given to target the optimal site for LV lead implantation away from myocardial scar and close to the latest LV site activation; and also to appropriately program the device paying particular attention to optimal atrioventricular and interventricular intervals. We herein review current data related to both optimal LV lead placement and device programming and their effects on CRT clinical outcomes.
Core tip: Cardiac resynchronization therapy has been established as a cornerstone therapy in symptomatic patients with heart failure, severe systolic left ventricular (LV) function and widened QRS complex. In order to achieve high percentage of biventricular pacing and to reduce the number of non-responders, consideration should be given to target the optimal site for LV lead implantation away from myocardial scar and close to the latest LV site activation; and also to appropriately program the device paying particular attention to optimal atrioventricular and interventricular intervals.